Cooper Companies (NASDAQ:COO) Releases Earnings Results, Beats Expectations By $0.03 EPS

Key Points

• Cooper Companies reported quarterly EPS of $1.15, beating expectations by $0.03, but revenue of $1.07 billion fell short of the $1.10 billion consensus estimate.
• Shares dropped 6.2% to $63.48 after the results, despite institutional investors owning 24.39% of the stock.
• Fiscal 2026 and fourth-quarter EPS guidance came in below consensus expectations, while analysts maintain a “Hold” consensus rating with an average price target of $81.64.

Cooper Companies (NASDAQ:COO - Get Free Report) released its quarterly earnings results on Wednesday. The medical device company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.12 by $0.03, Zacks reports. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies updated its Q4 2026 guidance to 1.050-1.090 EPS and its FY 2026 guidance to 4.510-4.550 EPS.

Cooper Companies Trading Down 6.2%

Shares of Cooper Companies stock traded down $4.21 during midday trading on Wednesday, reaching $63.48. The company had a trading volume of 8,383,881 shares, compared to its average volume of 2,347,124. The stock has a fifty day moving average price of $72.59 and a 200 day moving average price of $70.17. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The firm has a market cap of $12.38 billion, a PE ratio of 53.80, a P/E/G ratio of 1.82 and a beta of 0.82. Cooper Companies has a fifty-two week low of $58.89 and a fifty-two week high of $89.83.

Institutional Investors Weigh In On Cooper Companies

A number of institutional investors have recently modified their holdings of COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Cooper Companies by 48.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company's stock valued at $1,890,000 after acquiring an additional 7,363 shares during the last quarter. First Trust Advisors LP grew its stake in Cooper Companies by 115.8% during the second quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company's stock worth $9,702,000 after purchasing an additional 73,165 shares during the period. Cresset Asset Management LLC bought a new stake in Cooper Companies in the second quarter worth approximately $291,000. Cerity Partners LLC lifted its stake in Cooper Companies by 4.4% in the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company's stock valued at $1,272,000 after buying an additional 757 shares during the period. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Cooper Companies by 2.8% during the 2nd quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company's stock worth $2,551,000 after buying an additional 973 shares in the last quarter. 24.39% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. KeyCorp reaffirmed a "sector weight" rating on shares of Cooper Companies in a research note on Friday, June 5th. Needham & Company LLC dropped their target price on Cooper Companies from $101.00 to $86.00 and set a "buy" rating for the company in a research report on Friday, June 5th. Wall Street Zen upgraded Cooper Companies from a "hold" rating to a "buy" rating in a report on Sunday, June 21st. Mizuho set a $85.00 price objective on shares of Cooper Companies and gave the company an "outperform" rating in a report on Thursday, June 4th. Finally, UBS Group began coverage on shares of Cooper Companies in a research report on Tuesday, July 28th. They set a "neutral" rating and a $75.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Cooper Companies presently has an average rating of "Hold" and a consensus price target of $81.64.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

About Cooper Companies

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.